Cerium oxide nanoparticles (CNPs) have been proven to exhibit antioxidant properties attributed to its surface oxidation states (Ce4+ to Ce3+ and vice versa) mediated at the oxygen vacancies on the surface of CNPs. Different anions in precursor cerium salts were used to prepare CNPs resulting in disclosed CNPs with varying physicochemical properties such as dispersion stability, hydrodynamic size, and the signature surface chemistry. The antioxidant catalytic activity and oxidation potentials of different CNPs have been significantly altered with the change of anions in the precursor salts. For one, CNPs prepared using precursor salts containing NO.sub.3.sup.− and Cl.sup.− ions exhibited increased antioxidant activity than previously thought possible. The change in oxidation potentials of CNPs with the change in concentration of the nitrate and chloride ions indicates the disclosed CNP's have different surface chemistry and antioxidant properties. These compositions and methods of their synthesis are disclosed.

A powder intended for the manufacture of a sintered dental article, The powder has a chemical analysis such that, as weight percentages based on the oxides: Al.sub.2O.sub.3: 0.2%, oxides other than ZrO.sub.2, HfO.sub.2, Yb.sub.2O.sub.3, Y.sub.2O.sub.3 and Al.sub.2O.sub.3: <0.5%, and ZrO.sub.2+HfO.sub.2+Yb.sub.2O.sub.3+Y.sub.2O.sub.3: balance to 100%, with HfO.sub.2<2%. The contents of Yb.sub.2O.sub.3 and Y.sub.2O.sub.3, as molar percentages based on the sum of ZrO.sub.2, HfO.sub.2, Yb.sub.2O.sub.3 and Y.sub.2O.sub.3, being such that Yb.sub.2O.sub.3≥1%, 0.5%≤Y.sub.2O.sub.3<2%, and Yb.sub.2O.sub.3+Y.sub.2O.sub.3≤5.5%. The powder has a specific surface area of greater than or equal to 5 m.sup.2/g and less than or equal to 16 m.sup.2/g. The powder has a median size of greater than or equal to 0.1 μm and less than or equal to 0.7 μm.

A powder intended for the manufacture of a sintered dental article, The powder has a chemical analysis such that, as weight percentages based on the oxides: Al.sub.2O.sub.3: 0.2%, oxides other than ZrO.sub.2, HfO.sub.2, Yb.sub.2O.sub.3, Y.sub.2O.sub.3 and Al.sub.2O.sub.3: <0.5%, and ZrO.sub.2+HfO.sub.2+Yb.sub.2O.sub.3+Y.sub.2O.sub.3: balance to 100%, with HfO.sub.2<2%. The contents of Yb.sub.2O.sub.3 and Y.sub.2O.sub.3, as molar percentages based on the sum of ZrO.sub.2, HfO.sub.2, Yb.sub.2O.sub.3 and Y.sub.2O.sub.3, being such that Yb.sub.2O.sub.3≥1%, 0.5%≤Y.sub.2O.sub.3<2%, and Yb.sub.2O.sub.3+Y.sub.2O.sub.3≤5.5%. The powder has a specific surface area of greater than or equal to 5 m.sup.2/g and less than or equal to 16 m.sup.2/g. The powder has a median size of greater than or equal to 0.1 μm and less than or equal to 0.7 μm.

To provide a muscle tissue-regenerating agent containing a fibroin protein.

A muscle tissue-regenerating agent containing a modified fibroin protein.

The present invention relates to the use of spray-dried sorbitol, such as Parteck® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.

The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized using the processes disclosed herein.

The description provides a molecular switch comprising at least two nanoparticles, wherein a first nanoparticle comprises DNA and/or RNA oligonucleotides, and a second nanoparticle which is complementary to the first nanoparticle comprises reverse complementary DNA and/or RNA oligonucleotides of the first nanoparticle; wherein the complementary nanoparticles interact under physiological conditions leading to thermodynamically driven conformational changes in the first and second nanoparticles leading to their re-association to release one or more duplexes comprising said DNA and/or RNA oligonucleotides and the reverse complementary DNA and/or RNA oligonucleotides, and wherein the nanoparticles are not rings and have no single stranded toeholds.

The description provides a molecular switch comprising at least two nanoparticles, wherein a first nanoparticle comprises DNA and/or RNA oligonucleotides, and a second nanoparticle which is complementary to the first nanoparticle comprises reverse complementary DNA and/or RNA oligonucleotides of the first nanoparticle; wherein the complementary nanoparticles interact under physiological conditions leading to thermodynamically driven conformational changes in the first and second nanoparticles leading to their re-association to release one or more duplexes comprising said DNA and/or RNA oligonucleotides and the reverse complementary DNA and/or RNA oligonucleotides, and wherein the nanoparticles are not rings and have no single stranded toeholds.

Multiparticulate compositions including an active agent and a gelling agent are disclosed. The multiparticulate compositions are prepared by an aqueous-based spray and congeal process.

Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.